NY-UNIFRAX/CLEARLAKE
11.11.2021 13:02:09 CET | Business Wire | Press release
Unifrax , a leading manufacturer of high-performance specialty materials, today introduced its Battery Advisory Board, which will meet regularly to provide strategic guidance as Unifrax grows its battery portfolio and enters the silicon anode market with its new SiFAB™ Silicon Fiber Anode Battery Technology .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005282/en/
SiFAB, a scalable proprietary silicon anode battery technology demonstrated in wide-reaching applications, including electric vehicles, power tools, smartphones, personal computers, medical devices and aviation, can deliver up to 20% increase in gravimetric energy density in lithium-ion batteries. It has proven through advanced testing high reversible capacity of greater than 1,000 mAh/g. Unifrax recently broke ground on its first production line located in New Carlisle, IN, which is expected to come online in early 2022.
This transformational technology becomes part of a robust battery portfolio that also consists of world class thermal management products and separator media.
The advisory board will bring together four highly experienced professionals and visionaries in the battery technology, engineering and operations space, with experts from the nation’s top universities and esteemed technology companies.
Unifrax’s Battery Advisory Board will include:
- Dr. Prabhakar Patil, former CEO, LG Chem Power, and Chief Engineer of Hybrid Technologies, Ford Motor Company. Dr. Patil previously served as CEO of LG Chem Power (LGCPI) for 10 years. Prior to joining LGCPI in 2005, Dr. Patil spent 27 years of his professional career at Ford Motor Company in various engineering and management positions. He served as Chief Engineer for Ford’s hybrid technologies during 2003 and was also Chief Engineer for the Ford Escape Hybrid from 1998 to 2003.
- Rita Lane, former Vice President of Operations, Apple Inc., and Senior Vice President of Integrated Supply Chain, Motorola. Ms. Lane has more than 30 years of experience building and leading global hardware operations and supply chain teams for Fortune 100 companies. From 2008 until her retirement in 2014, she served as Vice President of Operations at Apple, where she oversaw the launch of the iPad and manufacturing of the Mac desktop and accessories product lines. From 2006 to 2008, Lane was Chief Procurement Officer and SVP, Supply Chain, at Motorola. Prior to working at Motorola, Lane held various senior-level operations roles at IBM for more than 10 years.
- Dr. Arumugam “Ram” Manthiram, Professor, University of Texas at Austin. Dr. Manthiram is Director of the Texas Materials Institute and the Materials Science and Engineering Graduate Program. With more than 35 years of experience, Dr. Manthiram’s research is focused on the development of low-cost, high-performance materials for batteries. He is a globally recognized leader in cathode materials for lithium-ion batteries. He has authored more than 850 journal articles. Dr. Manthiram holds the Cockrell Family Regents Chair in Engineering #5. He delivered the lecture on behalf of Nobel Prize recipient John B. Goodenough in 2019 in Stockholm for his work on lithium-ion batteries.
- Dr. Jennifer Rupp, Professor of Electrochemical Materials, Massachusetts Institute of Technology (MIT) and TU Munich (TUM). Dr. Rupp is Associate Professor of Electrochemical Materials in the Departments of Materials Science and Engineering at MIT and in the Department of Chemistry at TUM, and technical director of TUM Int. Energy. Dr. Rupp gave keynote lectures at Nature Energy and Sustainability conferences, Gordon Research keynote lectures in ceramics and electrochemistry and at the Royal Chemical Society, and presented on battery, information and energy technology at the World Economic Forum. Dr. Rupp’s team's current research focuses are on solid-state material design and tuning of structure-property relations for novel energy and information devices and operation schemes. In 2021, Rupp was invited to become a Fellow of the Royal Society of Chemistry (FRSC).
“We’re thrilled to have put together such a talented and influential advisory board,” said John Dandolph, CEO, Unifrax. “Their depth of experience and perspective in lithium-ion battery technology and novel chemistries spans multiple industries, including portable electronics, consumer devices and EVs, which will help us navigate the complex supply chains as we bring hundreds of metric tons of capacity to the market in the near future. I look forward to partnering with this group of industry icons as we transform battery safety, capacity, power, and charge times.”
To learn more about SiFAB or to follow the latest updates on the technology, visit www.sifab.com .
About Unifrax
Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has over 60 global manufacturing facilities and employs 5,600+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn and Facebook .
About Clearlake
Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit, and other related strategies. With a sector-focused approach, the firm seeks to partner with world-class management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are technology, industrials, and consumer. Clearlake currently has approximately $50 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005282/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom